Healthcare Sales & Marketing Network News: Daiichi Sankyo Group

Searching News Database: Daiichi Sankyo Group

HSMN NewsFeed - 12 Aug 2019
Daiichi Sankyo, Inc. Appoints Simon King as Chief People Officer across U.S. Divisions
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 Jul 2019
Results of the Pivotal Phase 3 Study of the Bempedoic Acid / Ezetimibe Combination Tablet Published in the European Journal of Preventative Cardiology Demonstrated Significant LDL-C Lowering
Biopharmaceuticals Cardiology

HSMN NewsFeed - 21 Jun 2019
Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 May 2019
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Apr 2019
Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Feb 2019
Daiichi Sankyo Europe and Esperion Announce Validation of the Marketing Authorisation Application (MAA) for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 22 Feb 2019
Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company's Launch into its Next Growth Phase
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Jan 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Nov 2018
EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 31 Aug 2018
Amneal Announces Partnership with American Regent on Generic Makena(R) and Progress on its Business Plan with Additional ANDA Approvals and Launches
Biopharmaceuticals Generics Distribution Product Launch

HSMN NewsFeed - 28 Aug 2018
Daiichi Sankyo Presents First Snapshot Analyses from Global ETNA-AF Programme of Oral, Once-daily LIXIANA(R) (edoxaban) in Patients with Nonvalvular Atrial Fibrillation in Routine Clinical Practice
Biopharmaceuticals

HSMN NewsFeed - 13 Aug 2018
New Analysis Identifies Patient Populations With Cancer-associated VTE Who Could Benefit From Treatment With Oral, Once-daily LIXIANA(R) (edoxaban)
Biopharmaceuticals

HSMN NewsFeed - 1 Aug 2018
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Jul 2018
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 8 May 2018
Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 Aug 2017
Daiichi Sankyo Terminates Development and Commercialization Agreement with Charleston Laboratories Regarding Hydrocodone Products in the U.S., including CL-108
Biopharmaceuticals

HSMN NewsFeed - 31 Aug 2017
Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Clinical Trial Evaluating Mirogabalin in Diabetic Peripheral Neuropathic Pain
Biopharmaceuticals

HSMN NewsFeed - 29 Aug 2017
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's DS-8201 for HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Aug 2017
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitor for Solid Tumors
Biopharmaceuticals Licensing

HSMN NewsFeed - 17 Jul 2017
CHMP Issues a Positive Opinion for Daiichi Sankyo's Once-Daily LIXIANA(R) (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 30 Jun 2017
Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes
Biopharmaceuticals

HSMN NewsFeed - 14 Jul 2016
Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
Biopharmaceuticals

HSMN NewsFeed - 16 Oct 2015
Daiichi Sankyo, Inc. Reorganizes its U.S. Commercial Operations to Support Upcoming Specialty Pipeline
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Aug 2015
NICE Recommends Once-daily Lixiana(R) (Edoxaban) for Preventing Stroke and Systemic Embolism in People with Non-valvular Atrial Fibrillation
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 19 Mar 2015
Daiichi Sankyo Signs Agreement With AstraZeneca To Co-Commercialize MOVANTIK In The US
Biopharmaceuticals

HSMN NewsFeed - 19 Feb 2015
FDA Grants Genentech�s Cobimetinib Priority Review for Use in Combination with Zelboraf (Vemurafenib) in Advanced Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Apr 2014
Ken Keller Named President, US Commercial, Daiichi Sankyo, Inc.
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 Mar 2014
Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion
Biopharmaceuticals Cardiology

HSMN NewsFeed - 3 Oct 2013
Daiichi Sankyo, Inc. Makes Two New Executive Appointments
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 May 2013
Plexxikon Announces Program Update and Management Changes
Biopharmaceuticals Personnel

HSMN NewsFeed - 17 Aug 2012
Ranbaxy Launches Authorized Generic Of Pioglitazone In The U.S.
Biopharmaceuticals Generics Endocrinology

HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Feb 2012
Plexxikon Announces European Approval of Zelboraf(R) for the Treatment of Patients With BRAF Mutation-Positive Metastatic Melanoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 13 Dec 2011
Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery
Biopharmaceuticals

HSMN NewsFeed - 17 Aug 2011
FDA Approves Zelboraf (Vemurafenib) and Companion Diagnostic for BRAF Mutation-Positive Metastatic Melanoma, a Deadly Form of Skin Cancer
Biopharmaceuticals Oncology Personalized Medicine FDA

HSMN NewsFeed - 17 Aug 2011
Daiichi Sankyo, Inc. Appoints Executive Vice President of Drug Development for the Americas
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Apr 2011
Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA(R) (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
Biopharmaceuticals Surgery Regulatory

HSMN NewsFeed - 4 Apr 2011
Daiichi Sankyo Completes Plexxikon Acquisition
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 16 Nov 2010
Mortality Data Presented for Patients Treated with Effient(R) Who Underwent Isolated Coronary Artery Bypass Surgery
Biopharmaceuticals Cardiology Surgery

HSMN NewsFeed - 26 Jul 2010
FDA Approves Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Jun 2010
New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes
Biopharmaceuticals

HSMN NewsFeed - 15 Mar 2010
Ranbaxy Announces Settlement of Actos(R) (Pioglitazone Hydrochloride) Patent Litigation
Biopharmaceuticals Generics Litigation

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.